GSK falls Wednesday, underperforms market
GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK outperforms market despite losses on the day
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
GSK Gets Positive Results in Blood-Cancer Drug Trial
Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...
Cancellation of kids’ asthma medication continues to cause turmoil for Mass. families
Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Relation-GSK to drive fibrotic and osteoarthritis developments
GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
FierceBiotech2d
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
FiercePharma3d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
biopharma-reporter2d
Relation and GSK join forces to advance fibrotic diseases and osteoarthritis therapies
Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and ...
GSK drug cut death risk by 42% in multiple myeloma study
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...